Haleos Labs Limited has recommended a final dividend of ₹1.50 per equity share for the financial year ended March 31, 2026 (FY26). The payout represents a 15% dividend on the face value of ₹10 per share.

The Board of Directors approved the recommendation during its meeting held on May 29, 2026. Shareholders must approve the dividend at the company’s 20th Annual General Meeting (AGM) before the payout is finalized.

Record Date and Payment

The record date for determining eligibility is September 23, 2026. Shareholders whose names appear in the Register of Members as at the close of business on this date will receive the dividend.

Payments will be made electronically to shareholders with registered bank accounts. Those without updated bank details will receive dividend warrants or demand drafts via post.

Tax Deduction at Source

Dividend income is taxable under the Income Tax Act, 2025. Haleos Labs will deduct Tax Deduction at Source (TDS) based on shareholder category and documentation.

Shareholders must submit necessary declarations, including Form 121 for tax exemption, by September 25, 2026. Failure to provide valid documentation may result in higher TDS rates.

What the Numbers Show

The declared dividend of ₹1.50 per share implies a total payout liability dependent on the outstanding equity capital. With no revenue or profit figures disclosed in this specific communication, the dividend yield cannot be calculated against current earnings. The focus remains on regulatory compliance for tax withholding rather than operational performance metrics.

The Board of Directors of Mahi Drugs Private Limited, a material subsidiary of Haleos Labs Limited (formerly known as SMS Lifesciences India Limited), convened a meeting on August 5, 2026, and approved two significant corporate actions — the appointment of a new Nominee Director and the appointment of Cost Auditors for the financial year 2026-27. The disclosures were made pursuant to Regulation 30(9) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Appointment of Nominee Director

Mr. Vincent P. Asaro has been appointed as the Nominee Director of Mahi Drugs Private Limited, as nominated by ChemWerth Inc., with effect from August 5, 2026. He replaces Mr. M. Madhu Rao, who ceased to be the Nominee Director of the subsidiary company with effect from the same date. The key details of the appointment are as follows:

Profile of Mr. Vincent P. Asaro

Mr. Asaro is a Certified Public Accountant (CPA) and holds an MBA in Finance from the University of Connecticut and a Bachelor of Science in Accounting from Providence College. He has also completed executive education at Harvard Business School. He is the President of ChemWerth Inc., a leading global developer and supplier of Active Pharmaceutical Ingredients (APIs) to regulated pharmaceutical markets worldwide.

With over 35 years of experience in finance, corporate strategy, business development, and pharmaceutical operations, Mr. Asaro has played a pivotal role in driving ChemWerth's growth and strengthening its global presence. Prior to his role as President, he served as the Chief Financial Officer of ChemWerth Inc. since 2009, where he led the company's financial strategy, operational excellence, and business expansion initiatives. Earlier in his career, he held finance and leadership positions with Deloitte & Touche and Bayer, gaining extensive expertise in accounting, auditing, internal controls, and corporate finance. He also serves on the Board of Directors of Bedoukian Research, Inc.

Appointment of Cost Auditors for FY 2026-27

The Board also approved the appointment of Annapragada & Co. as Cost Auditors of Mahi Drugs Private Limited for the financial year 2026-27, pursuant to the provisions of Section 148 of the Companies Act, 2013, read with Rule 14 and other applicable rules of the Companies (Audit and Auditors) Rules, 2014. The remuneration shall be subject to ratification by shareholders at the next Annual General Meeting.

Annapragada & Co. is a firm of Cost Accountants with experience in Cost Audits, Finance, Forecasting, and process improvement. The firm has demonstrated expertise in developing and implementing cost accounting systems, analysing cost trends, and providing accounting support to various operating groups and manufacturing plants, along with knowledge of relevant government regulations, internal controls, cost accounting methods, and cost modelling tools.

Disclosure and Compliance

The above developments were communicated to BSE Limited and the National Stock Exchange of India Limited by Trupti Ranjan Mohanty, Company Secretary of Haleos Labs Limited, in accordance with applicable listing regulations. The information is also available on the company's website at www.haleoslabs.com .